Published in final edited form as:

Org Prep Proced Int. 2005 December ; 37(6): 546–550.

**AN EFFICIENT SYNTHESIS OF TRICYCLIC COMPOUNDS, (±)-
(4a β 8a β 10 α)-1,2,3,4,4a,6,7,8,8a,9,10,10a-
DODECAHYDRO-1,1,4a-TRIMETHYL-2-OXOPHENANTHRENE-8a-
CARBOXYLIC ACID, ITS METHYL ESTER, AND (±)-(4a β ,
8a β 10 α)-3,4,4a,6,7,8,8a,9,10,10a-DECAHYDRO-8a-
HYDROXYMETHYL-1,1,4a-TRIMETHYLPHENANTHREN-2(1*H*)-
ONE**

Tadashi Honda, Yukiko Honda, Hidenori Yoshizawa, and Gordon W. Gribble

Department of Chemistry, Dartmouth College, Hanover, NH 03755

Our ongoing efforts for the improvement of anti-inflammatory and antiproliferative activity of oleanolic acid analogues led us to discover 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid (CDDO, **1**) and related compounds.¹

In connection with these investigations, we have found that tricyclic compounds with similar enone functionalities in rings A and C are also a novel class of highly active inhibitors of nitric oxide (NO) production in mouse macrophages.² In particular, *bis*-cyano enone ($\pm$)-**2** is orally active in a preliminary in vivo inflammation model.² In addition, we have found that (+)-**2** having the opposite configuration to that of CDDO shows 10 times higher inhibitory activity than (-)-**2** on NO production in mouse macrophages.³

These results encouraged us to design and synthesize analogues of **2**. Thus, we focused our attention on the modifications of the C-8a position, because some biologically active natural products have functionalities at the same position (e.g., anti-tumor quassinoids⁴). For our

projected synthesis of C-8a functionalized TBE compounds, the simple tricycles **3-5** are potentially very desirable intermediates.

We envisioned preparing **3-5** from the known acid **6**,⁶ by standard reductive methylation.⁷ However, attempts to reductively methylate acid **6** with 5-7 equivalents of lithium in liquid ammonia containing no proton donor, followed by esterification with diazomethane gave **4** in 30% yield (average of 7 experiments, the yield fluctuates) along with many by-products. These by-products caused serious difficulty for the purification of **4**. An attempt with one equivalent of *tert*-butanol gave similar results as without a proton donor. Attempts to reductively methylate methyl ester **7**,⁶ which is prepared from **6** with diazomethane, using 10 equivalents of lithium in liquid ammonia containing no proton donor gave the desired compounds **3-5** in low yield along with several by-products including enones **6** and **8**.

After much experimentation, we have found that the addition of one equivalent of water dramatically improves this reductive methylation reaction. Thus, the reductive methylation of **7** using 7.2 equivalents of lithium and *one equivalent of water* followed by quenching the excess lithium with isoprene, and then methyl iodide at -78 °C cleanly produced **3-5** in 38%, 15%, and 36% yields (total 89%), respectively. The yields are reproducible and we have prepared **3-5** several times by this procedure. These compounds can be easily separated by extracting the acid with aqueous base, followed by column chromatography (see Experimental Section). Also, they were easily converted to a single compound. For example, oxidation (e.g., Jones reagent and RuO₂-NaIO₄ etc.) of alcohol **5** gave acid **3**, and both acid **3** and methyl ester **4** were converted to alcohol **5** in three steps (ketalization, reduction with LiAlH₄, and deketalization). Acid **3** may be an important intermediate for the synthesis of abietane and totarane diterpenoids.

EXPERIMENTAL SECTION

Melting points were determined on a capillary melting point apparatus and are uncorrected. ¹H and ¹³C NMR spectra were recorded at 300 MHz or 75 MHz, respectively.

Elemental analyses were performed by Atlantic Microlab, Inc, Norcross, GA. THF was purified by a solvent purification system. All other solvents (analytical grade) and reagents were used as received.

(±)-(4aβ,8aβ,10aα)-1,2,3,4,4a,6,7,8,8a,9,10,10a-Dodecahydro-1,1,4a-trimethyl-2-oxophenanthrene-8a-carboxylic acid (3), Its Methyl Ester (4), and (±)-(4aβ,8aβ,10aα)-3,4,4a,6,7,8,8a,9,10,10a-Decahydro-8a-hydroxymethyl-1,1,4a-trimethylphenanthren-2(1H)-one (5)

To liquid ammonia (100 mL) was added lithium (600 mg, 86 mmol, 7.2 eq, sliced ribbon). The solution was stirred at -78 °C for 15 min. Compound **7⁶** (3.5 g, 12 mmol) and water (218 mg, 12 mmol, 1 eq) in THF (47 mL) were added dropwise and the mixture was stirred under reflux at -33 °C (bp of ammonia) (with the aid of a CCl₄ bath) for 1 h. The mixture was cooled to -78 °C and isoprene (approx. 1.25 mL) was injected until the blue color disappeared turning the solution cloudy white. To this mixture were successively added THF (17.5 mL) and iodomethane (17.5 mL) dropwise. The reaction mixture was stirred under reflux at -33 °C for 1 h. After removal of the ammonia with the aid of a nitrogen stream, 10% aqueous HCl (2 × 60 mL, 2 × 30 mL) was added to the mixture to acidify. The acidic mixture was extracted with CH₂Cl₂ (4 × 50 mL). The combined organic extracts were washed with brine (2 × 25 mL), dried over MgSO₄, filtered and concentrated in vacuo to give 3.8 g of crude product. A solution of the material in ethyl acetate (100 mL) was extracted with 5% aqueous NaOH solution (2 × 25 mL) and water (1 × 25 mL). The aqueous basic extract was acidified with 10% aqueous HCl to give a cloudy suspension. The acidic aqueous mixture was extracted with ethyl acetate (3 × 25 mL). The extract was washed with water (3 × 25 mL), brine (1 × 25 mL), dried over MgSO₄, and filtered. The filtrate was evaporated in vacuo to give acid **3** as an amorphous solid (1.33 g, 38%). The organic layer including neutral compounds was washed with saturated aqueous ammonium chloride (2 × 25 mL) and brine (2 × 25 mL), dried over MgSO₄, and filtered. The filtrate was evaporated in vacuo to give a residual oil (2.33 g) that was purified by flash column chromatography [hexanes:EtOAc 3:1, followed by 2:1] to give methyl ester **4** (547 mg, 15%) and alcohol **5** (1.21 g, 36%) as crystalline solids.

Acid **3**: IR (KBr): 3200, 2943, 1691, 1457 cm⁻¹. ¹H NMR (CDCl₃): δ 5.72 (1 H, dd, *J* = 3.1, 4.6 Hz), 2.73 (1 H, ddd, *J* = 6.3, 13.6, 15.8 Hz), 2.58 (1 H, dt, *J* = 3.2, 13.4 Hz), 2.41 (1 H, ddd, *J* = 3.0, 5.2, 15.8 Hz), 2.20-1.20 (13 H m)⁸ 1.16, 1.06, 1.04 (3 H each, s). ¹³C NMR (CDCl₃): δ 217.0, 183.3, 144.5, 122.4, 54.5, 48.0, 45.5, 40.2, 38.34, 38.27, 36.8, 35.0, 25.8, 25.5, 22.2, 21.04, 21.03, 18.0. EIMS (70 eV) *m/z*: 290 [M⁺] (20), 245 (26), 91 (100). HREIMS: Calcd for C₁₈H₂₆O₃ 290.1882. Found: 290.1880.

Anal. Calcd for C₁₈H₂₆O₃·1/4 H₂O: C, 73.31; H, 9.06. Found: C, 73.52; H, 8.92.

Methyl ester **4**: mp 90-92 °C. IR (KBr): 2941, 2858, 1716, 1445 cm⁻¹. ¹H NMR (CDCl₃): δ 5.68 (1 H, dd, *J* = 3.5, 4.6 Hz), 3.70 (3 H, s), 2.73 (1 H, ddd, *J* = 6.4, 13.6, 16.0 Hz), 2.60 (1 H, dt, *J* = 3.3, 13.3 Hz), 2.41 (1 H, ddd, *J* = 3.0, 5.2, 16.0 Hz), 2.30-1.06 (12 H, m),⁸ 1.06 (6 H, s), 1.03 (3 H, s). ¹³C NMR (CDCl₃): δ 216.7, 177.4, 145.1, 121.8, 54.6, 51.9, 47.9, 45.6, 40.1, 38.6, 38.3, 36.8, 35.0, 25.8, 25.6, 22.1, 21.0, 20.0, 18.2. EIMS (70 eV) *m/z*: 304 [M⁺] (31), 245 (100), 159 (33). HREIMS: Calcd for C₁₉H₂₈O₃ 304.2038. Found: 304.2039.

Anal. Calcd for C₁₉H₂₈O₃·1/5 H₂O: C, 74.09; H, 9.29. Found: C, 73.99; H, 9.22.

Alcohol **5**: mp 109-110 °C. IR (KBr): 3454, 2931, 2859, 1645, 1448 cm⁻¹. ¹H NMR (CDCl₃): δ 5.67 (1 H, t, *J* = 3.8 Hz), 3.68 (2 H, s), 2.68 (1 H, ddd, *J* = 6.6, 12.5, 15.7 Hz), 2.43 (1 H, ddd, *J* = 3.3, 5.9, 15.7 Hz), 2.20-1.00 (14 H, m)⁸ 1.20 (3 H, d, *J* = 0.6 Hz), 1.08 (3 H, s), 1.06 (3 H, s). ¹³C NMR (CDCl₃): δ 217.0, 148.0, 123.0, 67.0, 54.1, 47.9, 39.7, 39.0, 38.0, 37.1, 36.7, 34.9, 26.1, 26.0, 22.6, 21.8, 19.7, 18.1. EIMS (70 eV) *m/z*: 276 [M⁺] (6.1), 245 (100), 227 (10), 203 (6.1). HREIMS: Calcd for C₁₈H₂₈O₂ 276.2089. Found: 276.2082.

Anal. Calcd for C₁₈H₂₈O₂: C, 78.21; H, 10.21. Found: C, 77.92; H, 10.12.

Acknowledgment

We thank Dr. Steven Mullen (University of Illinois) for the mass spectra. This investigation was supported by funds from NIH Grant 5R03-CA105294.

REFERENCES

- 1(a). Honda T, Finlay HJ, Gribble GW, Suh N, Sporn MB. *Bioorg. Med. Chem. Lett* 1997;7:1623. (b) Honda T, Rounds BV, Gribble GW, Suh N, Wang Y, Sporn MB. *Bioorg. Med. Chem. Lett* 1998;8:2711. [PubMed: 9873608] (c) Honda T, Rounds BV, Bore L, Favalaro FG Jr. Gribble GW, Suh N, Wang Y, Sporn MB. *Bioorg. Med. Chem. Lett* 1999;9:3429. [PubMed: 10617085] (d) Honda T, Gribble GW, Suh N, Finlay HJ, Rounds BV, Bore L, Favalaro FG Jr. Wang Y, Sporn MB. *J. Med. Chem* 2000;43:1866. [PubMed: 10794703] (e) Honda T, Rounds BV, Bore L, Finlay HJ, Favalaro FG Jr. Suh N, Wang Y, Sporn MB, Gribble GW. *J. Med. Chem* 2000;43:4233. [PubMed: 11063620] (f) Honda T, Honda Y, Favalaro FG Jr. Gribble GW, Suh N, Place AE, Rendi MH, Sporn MB. *Bioorg. Med. Chem. Lett* 2002;12:1027. [PubMed: 11909709]
2. Favalaro FG Jr. Honda T, Honda Y, Gribble GW, Suh N, Risingsong R, Sporn MB. *J. Med. Chem* 2002;45:4801. [PubMed: 12383005]
3. Honda T, Favalaro FG Jr. Janosik T, Honda Y, Suh N, Sporn MB, Gribble GW. *Org. Biomol. Chem* 2003;1:4384. [PubMed: 14685310]
4. Cassady, JM.; Suffness, M. *Anticancer Agents Based on Natural Product Models*. Academic Press; New York, NY: 1980. p. 254
5. Snitman DL, Watt DS. *Synth. Commun* 1978;8:187.
6. Kerwin SM, Paul AG, Heathcock CH. *J. Org. Chem* 1987;52:1686.
7. Caine D. *Org. React* 1976;23:1.and references cited therein.
8. Overlapped signals which cannot be assigned.